

## Pfizer Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

URL:	<a href="https://marketpublishers.com/r/P5E858AABB7BEN.html">https://marketpublishers.com/r/P5E858AABB7BEN.html</a>
Date:	July 1, 2018
Pages:	50
Price:	US\$ 499.00
ID:	P5E858AABB7BEN

Pfizer Inc. Fundamental Company Report provides a complete overview of the company's affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Pfizer Inc. and its competitors. This provides our Clients with a clear understanding of Pfizer Inc. position in the **Pharmaceuticals and Biotechnology Industry**.

- The report contains detailed information about Pfizer Inc. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
- Another part of the report is a SWOT-analysis carried out for Pfizer Inc.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company's strengths, weaknesses, opportunities, and possible threats against it.
- The Pfizer Inc. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company's long-term solvency. This sort of company's information will assist and strengthen your company's decision-making processes.
- In the part that describes Pfizer Inc. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company's competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company's business and sales activities will be boosted by gaining an insight into your competitors' businesses.
- Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Pfizer Inc. business.

### About Pfizer Inc.

Pfizer Inc. engages in the discovery, development, manufacture, and marketing of prescription medicines for humans and animals worldwide. The company's global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer health care products.

### Segments

The company's segments include Biopharmaceutical and Diversified.

## Biopharmaceutical

Biopharmaceutical includes the Primary Care, Specialty Care, Established Products, Emerging Markets and Oncology customer-focused units, which include products that prevent and treat cardiovascular and metabolic diseases, central nervous system disorders, arthritis and pain, infectious and respiratory diseases, urogenital conditions, cancer, eye disease, and endocrine disorders.

## Products

**Lipitor:** It is used for the treatment of elevated LDL-cholesterol levels in the blood. It is a branded prescription treatment for lowering cholesterol.

**Norvasc:** It is used for treating hypertension, lost exclusivity in the U.S. in 2007 and has also experienced patent expirations in most other major markets, including Japan and Canada.

**Caduet:** It is a single pill therapy combining Lipitor and Norvasc for the prevention of cardiovascular events.

**Chantix/Champix:** It is a prescription treatment to aid smoking cessation.

Chantix benefit-risk proposition, the significant health consequences of smoking and the importance of the physician-patient dialogue in helping patients quit smoking.

**Lyrica:** It is indicated for the management of post-herpetic neuralgia (PHN), diabetic peripheral neuropathy (DPN), fibromyalgia, and as adjunctive therapy for adult patients with partial onset seizures in the U.S., and for neuropathic pain, adjunctive treatment of epilepsy and general anxiety disorder (GAD) outside the U.S.

**Revatio:** It is used for the treatment of pulmonary arterial hypertension.

**Geodon/Zeldox,** a psychotropic agent, is a dopamine and serotonin receptor antagonist indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar disorder and maintenance treatment of bipolar mania.

**Aricept:** It is discovered and developed by Eisai Co., Ltd. It is a medicine to treat symptoms of Alzheimer's disease. The company co-promotes Aricept with Eisai in the U.S. and various other countries and has a license to sell this medicine in certain other countries.

**Celebrex:** It is used for the treatment of the signs and symptoms of osteoarthritis and rheumatoid arthritis and acute pain in adults.

**Zyvox:** It is used for the treatment of certain serious Gram-positive pathogens, including Methicillin-Resistant Staphylococcus-Aureus.

**Viagra:** It is a treatment for erectile dysfunction.

**Detrol/Detrol LA,** a muscarinic receptor antagonist, is the most prescribed branded medicine worldwide for overactive bladder. Detrol LA is an extended-release formulation taken once a day.

**Sutent:** It is for the treatment of advanced renal cell carcinoma, including metastatic renal cell carcinoma (mRCC), and gastrointestinal stromal tumors (GIST) after disease progression on, or intolerance to, imatinib mesylate.

**Xalatan,** a prostaglandin, is the branded agent to reduce elevated eye pressure in patients with open-angle

glaucoma or ocular hypertension. Xalacom, a fixed combination prostaglandin (Xalatan) and beta blocker (timolol), is available outside the U.S. In 2009, the company entered into a five-year agreement with Bausch & Lomb to co-promote prescription pharmaceuticals in the U.S. for the treatment of ophthalmic conditions, including its Xalatan product and certain Bausch & Lomb products.

Genotropin: It is used in children for the treatment of short stature with growth hormone deficiency, Prader-Willi Syndrome, Turner Syndrome, Small for Gestational Age Syndrome, Idiopathic Short Stature (in the U.S.) and Chronic Renal Insufficiency (outside the U.S.), as well as in adults with growth hormone deficiency. Genotropin is supported by a platform of injection-delivery devices.

Vfend: It is a branded agent available in intravenous and oral forms.

Effexor is the company's antidepressant.

The above Company Fundamental Report is a half-ready report and contents are subject to change. It means that we have all necessary data in our database to prepare the report but need **2-3 days** to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.

## Table of Content

### RESEARCH METHODOLOGY

### DISCLAIMER

## 1. PFIZER INC. COMPANY PROFILE

- 1.1. Key facts
- 1.2. Financial Performance
- 1.3. Key Executives
- 1.4. Ownership and Major Holders
- 1.5. Company History

## 2. PFIZER INC. BUSINESS OVERVIEW

- 2.1. Business Description
- 2.2. Major Products and Services
- 2.3. Markets and Sales Activities
- 2.4. Locations, Subsidiaries, Operating Units

## 3. PFIZER INC. SWOT ANALYSIS

- 3.1. Overview
- 3.2. Strengths
- 3.3. Weaknesses
- 3.4. Opportunities
- 3.5. Threats

## 4. PFIZER INC. FINANCIAL ANALYSIS

- 4.1. Financial Statements
  - 4.1.1. Income Statement

- 4.1.2. Balance Sheet
- 4.1.3. Cash Flow
- 4.2. Financial Ratios
  - 4.2.1. Profitability
  - 4.2.2. Margin Analysis
  - 4.2.3. Asset Turnover
  - 4.2.4. Credit Ratios
  - 4.2.5. Long-Term Solvency
  - 4.2.6. Growth Over Prior Year
  - 4.2.7. Financial Ratios Charts
- 4.3. Stock Market Snapshot

## **5. PFIZER INC. COMPETITORS AND INDUSTRY ANALYSIS**

- 5.1. Pfizer Inc. Direct Competitors
- 5.2. Comparison of Pfizer Inc. and Direct Competitors Financial Ratios
- 5.3. Comparison of Pfizer Inc. and Direct Competitors Stock Charts
- 5.4. Pfizer Inc. Industry Analysis
  - 5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  - 5.4.2. Pfizer Inc. Industry Position Analysis

## **6. PFIZER INC. NEWS & EVENTS**

- 6.1. News & PR Activity Analysis
- 6.2. IR Corporate News
- 6.3. Marketing News
- 6.4. Corporate Events

## **7. PFIZER INC. EXPERTS REVIEW<sup>1</sup>**

- 7.1. Experts Opinion
- 7.2. Experts Estimates

## **8. PFIZER INC. ENHANCED SWOT ANALYSIS<sup>2</sup>**

## **9. UNITED STATES PESTEL ANALYSIS<sup>2</sup>**

- 9.1. Political Factors
- 9.2. Economic Factors
- 9.3. Social Factors
- 9.4. Technological Factors
- 9.5. Environmental Factors
- 9.6. Legal Factors

## **10. PFIZER INC. IFE, EFE, IE MATRICES<sup>2</sup>**

- 10.1. Internal Factor Evaluation Matrix
- 10.2. External Factor Evaluation Matrix
- 10.3. Internal External Matrix

## **11. PFIZER INC. PORTER FIVE FORCES ANALYSIS<sup>2</sup>**

## **12. PFIZER INC. VRIO ANALYSIS<sup>2</sup>**

## **APPENDIX: RATIO DEFINITIONS**

**LIST OF TABLES**

Pfizer Inc. Key Facts  
Profitability  
Management Effectiveness  
Income Statement Key Figures  
Balance Sheet Key Figures  
Cash Flow Statement Key Figures  
Financial Performance Abbreviation Guide  
Pfizer Inc. Key Executives  
Key Executives Biographies<sup>1</sup>  
Key Executives Compensations<sup>1</sup>  
Pfizer Inc. Major Shareholders  
Pfizer Inc. History  
Pfizer Inc. Products  
Revenues by Segment  
Revenues by Region  
Pfizer Inc. Offices and Representations  
Pfizer Inc. SWOT Analysis  
Yearly Income Statement Including Trends  
Income Statement Latest 4 Quarters Including Trends  
Yearly Balance Sheet Including Trends  
Balance Sheet Latest 4 Quarters Including Trends  
Yearly Cash Flow Including Trends  
Cash Flow Latest 4 Quarters Including Trends  
Pfizer Inc. Profitability Ratios  
Margin Analysis Ratios  
Asset Turnover Ratios  
Credit Ratios  
Long-Term Solvency Ratios  
Financial Ratios Growth Over Prior Year  
Pfizer Inc. Capital Market Snapshot  
Pfizer Inc. Direct Competitors Key Facts  
Direct Competitors Profitability Ratios  
Direct Competitors Margin Analysis Ratios  
Direct Competitors Asset Turnover Ratios  
Direct Competitors Credit Ratios  
Direct Competitors Long-Term Solvency Ratios  
Pharmaceuticals and Biotechnology Industry Statistics  
Pfizer Inc. Industry Position  
Company vs. Industry Income Statement Analysis  
Company vs. Industry Balance Sheet Analysis  
Company vs. Industry Cash Flow Analysis  
Company vs. Industry Ratios Comparison  
Pfizer Inc. Consensus Recommendations<sup>1</sup>  
Analyst Recommendation Summary<sup>1</sup>  
Price Target Summary<sup>1</sup>  
Experts Recommendation Trends<sup>1</sup>  
Revenue Estimates Analysis<sup>1</sup>  
Earnings Estimates Analysis<sup>1</sup>  
Historical Surprises<sup>1</sup>  
Revenue Estimates Trend<sup>1</sup>  
Earnings Estimates Trend<sup>1</sup>  
Revenue Revisions<sup>1</sup>

## LIST OF FIGURES

Pfizer Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit  
Profit Margin Chart  
Operating Margin Chart  
Return on Equity (ROE) Chart  
Return on Assets (ROA) Chart  
Debt to Equity Chart  
Current Ratio Chart  
Pfizer Inc. 1-year Stock Charts  
Pfizer Inc. 5-year Stock Charts  
Pfizer Inc. vs. Main Indexes 1-year Stock Chart  
Pfizer Inc. vs. Direct Competitors 1-year Stock Charts  
Pfizer Inc. Article Density Chart

1 – Data availability depends on company's security policy.

2 – These sections are available only when you purchase a report with appropriate additional types of analyses.

The complete financial data is available for publicly traded companies.

### I would like to order:

**Product name:** Pfizer Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis  
**Product link:** <https://marketpublishers.com/r/P5E858AABB7BEN.html>  
**Product ID:** P5E858AABB7BEN  
**Price:** US\$ 499.00 (Single User License / Electronic Delivery)

*If you want to order Corporate License or Hard Copy, please, contact our Customer Service: [office@marketpublishers.com](mailto:office@marketpublishers.com)*

### Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <https://marketpublishers.com/r/P5E858AABB7BEN.html>

### To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
E-mail:  
Company:  
Address:  
City:  
Zip/Post Code:  
Country:  
Tel:  
Fax:  
Your message:

\* All fields are required

Customer Signature \_\_\_\_\_

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at [https://marketpublishers.com/docs/terms\\_conditions.html](https://marketpublishers.com/docs/terms_conditions.html)

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**